



ANNUAL SCIENTIFIC
EDUCATION PROGRAM

Physicians - Management - Technicians

June 10, 2011
Aqua Turf
Plantsville, Connecticut



Printed on 100% recycled paper using vegetable based ink.

SPECIAL ACKNOWLEDGMENT AND
THANKS

to our

PLATINUM EXHIBITORS contributing \$5,000 or
more in support of our Educational Program

Alcon Laboratories
Allergan
Genentech

GOLD EXHIBITORS contributing \$2,500 or more
in support of our Educational Program

McLeod Optical Company
Precision Optical

SPECIAL ACKNOWLEDGMENT AND THANKS
to our Silver Exhibitors contributing up to \$1,000

Abbott Medical Optics

IOP/FCI Ophthalmics

Carl Zeiss Meditec

Ista Pharmaceuticals

CT Library for the Blind

Katena Instruments

DavLong Business
Solutions

Lions Low Vision

EndoOptiks, Inc.

Keep Sight

Marco

Fallon Wellness Pharmacy

Optovue

Heidelberg Engineering

Tura

Informed M.D.com

Inspire Pharmaceuticals

IO Practiceware

PHYSICIANS PROGRAM

8:00 Registration and Continental Breakfast
–Vendor Expo

8:30 **Pseudoexfoliation**
– Steve Lane, M.D.

Objectives: 1. Describe the clinical findings seen in Pseudoexfoliation 2. Describe the key features to look for in assessing the pseudoexfoliation patient for cataract surgery 3. Discuss the intraoperative management and potential complications the cataract surgeon might encounter during cataract surgery.

9:30 **2011 Neuro-ophthalmology Film Festival**
– Steve Galetta, M.D.

Objectives: To discuss the common forms of nystagmus, to detect common pupillary disorders and describe ocular oscillations that mimic nystagmus.

10:30 Coffee, tea and pastries will be served in the Exhibit Hall

11:00 **The Future of Cataract Surgery and IOLs**
– Steve Lane, M.D.

Objectives: 1. Discuss the difference between true and pseudo accommodation 2. Discuss the difference

PHYSICIANS PROGRAM

between the Multifocal IOLs currently FDA approved.
3. Describe the limitations of current cataract surgery and how Femtosecond refractive cataract surgery addresses them.

11:45 **Business Meeting**

12:15 **Lunch - Robert Vare, Keynote Author**

1:15 **Health Care Reform – An Update for Ophthalmologists**

– Michael Repka, M.D., AAO Medical Director of Governmental Affairs

Objective: To Understand the Current Status of the Accountable Care Act and its Likely Impact on Ophthalmologists.

2:00 **Optic Neuritis: A Novel Paradigm for Neuro-Protection**

– Steve Galetta, M.D.

Objectives: 1. Discuss the clinical features and differential diagnosis of optic neuritis. 2. Discuss the role of OCT and low contrast acuity testing in neuro-protection. 3. Understand the importance of visual outcome measures in recent clinical trials.

PHYSICIANS PROGRAM

- 3:00 Yale Poster Session – International Coffees, Teas and English Pastries will be served in the Exhibit Hall
- 3:30 **Lessons in the Treatment of Amblyopia From Recent Clinical Trials**
– Michael Repka, M.D., AAO Medical Director of Governmental Affairs
Objective: To Describe the Unexpected Findings of a Series of Clinical Trials in the Management of Amblyopia.
- 4:30 CME Certificates, Yale Resident and Fellow Poster Awards and Door Prizes

The Connecticut Society of Eye Physicians designates this educational activity for a maximum of 7 AMA PRA Category I Credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The Connecticut Society of Eye Physicians is accredited by the Connecticut State Medical Society to sponsor continuing medical education for physicians.

SPEAKERS



HANS BRUHN, BS, MHS

Hans Bruhn has more than 28 years experience working in the commercial insurance industry, over 21 years of those exclusively in the medical malpractice/professional liability insurance field. Hans has worked for several national medical malpractice insurance companies and brokers during his career. Currently, he is a Senior Risk Management Specialist with Ophthalmic Mutual Insurance Company (OMIC) based in San Francisco, California. In his current position, Hans works with physicians and their staff, advising them on how to reduce the risk of medical malpractice claims in their practice. In addition, Hans travels across the United States, giving presentations to various medical and subspecialty societies on risk management topics. He is also a contributing writer on risk management topics for OMIC and other publications.

Hans earned a Bachelor of Science degree in education (BS-Ed) from The University of Wisconsin and a Masters of Science in Health Services Administration (MHS) degree from Saint Mary's

SPEAKERS

College in Moraga, CA.

Hans lives in the San Francisco Bay Area with his wife and daughter.



PAMELA B. FRITZ

Ms. Fritz, President of Ophthalmology Resources, LLC is an optical industry consultant who specializes in dispensing ophthalmology. Her years of successful for MD's is well documented with testimonials by MD's nationwide.

She has given hundreds of seminars at the Vision Expo (East & West), the Academy of Ophthalmology Annual Meeting, state MD societies and opticians associations. She is a specialist in Medicare Post-op Cataract Eyewear billing, coding and compliancy, with workshops at the Academy of Ophthalmology and many state ophthalmological and opticians associations. She is a contributing editor of the AAO's Medicare DME coding and billing module. She serves on three DME Medicare Contractors Advisory Panels, covering the Northeast, Mid-west and Western, US. In 2003 she was named, "50 of the

SPEAKERS

most influential women in the optical industry" in a nationwide poll conducted by Jobson Publishing. She has served as the Executive Director of the American Assoc. of Dispensing Ophthalmologists, Inc. She writes for Review of Ophthalmology and EyeCare Business publications.



STEVEN GALETTA, MD

Dr. Galetta is currently the Van Meter Professor of Neurology at the University of Pennsylvania, Director, Neuro-Ophthalmology Services; Residency Director, Department of Neurology. Dr. Galetta received his MD from Cornell University Medical College. He then completed his neurology residency at the Hospital of the University of Pennsylvania and his neuro-ophthalmology fellowship at Bascom Palmer Eye Institute, University of Miami.

Dr. Galetta has served on the editorial board for the journals *Neurology*, *Journal of Neuro-Ophthalmology*, and the *American Journal of Neuro-Radiology*. He is co-author of the textbook,

SPEAKERS

Neuro-ophthalmology: Diagnosis and Management. In 2004, he was named the American Neurological Association's distinguished teacher of the year. He was also named the Robert J. Glaser Alpha Omega Alpha distinguished teacher of the year by the Association of American Medical Colleges in 2004. In 2008, he received the Parker Palmer award from the ACGME. Dr. Galetta has been involved in various capacities in a large number of clinical trials and has over 200 original publications concerning clinical, radiologic and research aspects of multiple sclerosis and neuro-ophthalmology.



STEPHEN S. LANE, MD

Stephen S. Lane, MD is Medical Director at Associated Eye Care in Minnesota., Adjunct Professor of Ophthalmology at the University of Minnesota, and a visiting faculty member of ORBIS International. Dr. Lane completed his medical degree from the University of Minnesota, ophthalmology residency at Pennsylvania State University, and cornea and exter-

SPEAKERS

nal disease fellowship at the University of Minnesota.

Dr. Lane's expertise is in cataract surgery, cornea/external disease, anterior segment surgery and refractive surgery. Research activities include more than 30 grants concentrating on Cataract Surgery, Refractive Surgery, Corneal surgery, and External diseases. He has lectured around the world and has authored over 60 peer-reviewed articles and 20 book chapters, and given more than 15 named lectures. He is past president of ASCRS and currently sits on the board of the ASCRS Foundation, and on the board of ASCRS. He was the first secretary of e-Learning and e-Education at the American Academy of Ophthalmology and has sat on the Committee of Secretaries for the AAO as well as on the boards of the Minnesota Academy of Ophthalmology and ISRS. Dr. Lane serves on the editorial boards of several ophthalmic journals including *The Journal of Cataract and Refractive Surgery*. He is also the former Medical co-editor of *EyeWorld*. His recognitions include Who's Who in America, Who's Who in the World, Best Doctors in America, and American Academy of Ophthalmology Senior

SPEAKERS

Achievement and Secretariat Awards.



PAUL M. LARSON, MMSc, MBA, COMT, COE, CPC

Paul is an Associate Consultant with Corcoran Consulting Group. He began his career in ophthalmology in 1976 while in the United States Navy and received his credential as a Certified Ophthalmic Medical Technologist (COMT) through the Joint Commission of Allied Health Professionals in Ophthalmology (JCAHPO) in 1984. He has held program director and faculty positions at both COT- and COMT-based training programs, educating ophthalmic technology students and ophthalmology residents, and most recently served as Senior Clinical Operations Manager at a large academic practice. He has had an active role in Clinical trials. In 2003 he received his Certified Ophthalmic Executive (COE) certification, and additionally received his Master of Business Administration with specialization in Healthcare Management from Regis University in 2005. He served as President,

SPEAKERS

Association of Technical Personnel in Ophthalmology (ATPO) on two separate occasions; in 1991 he was honored by being named a Fellow of the organization. He served as the President of the Consortium of Ophthalmic Training Programs from 2006-2007, and also served on the American Society of Ophthalmic Administrators' (ASOA) Board of Governors as a Member-at-large from 2009-2010. He maintains his certification as a COMT and continues to enjoy the clinical aspects of ophthalmology. He remains active in ATPO and ASOA and teaches various workshops at the annual meetings. He has presented nationally and regionally on both clinical and administrative topics, and has authored or co-authored many clinical and administrative articles.

Paul conducts business from Corcoran Consulting Group's Georgia office.

SPEAKERS



MICHAEL REPKA, MD

Dr. Repka received his medical degree from the Jefferson Medical College of Thomas Jefferson University and completed his ophthalmology residency at Wills Eye Hospital. Following completion of his residency training, a fellowship was spent training in pediatric ophthalmology and strabismus as well as neuro-ophthalmology at the Wilmer Ophthalmological Institute of Johns Hopkins Hospital.

Dr. Repka is the David L. Guyton, MD and Feduniak Family Professor of Ophthalmology and a professor of pediatrics at the Johns Hopkins University School of Medicine. He has been at the Johns Hopkins University School of Medicine since 1983. He is known for his contributions in the fields of pediatric ophthalmology, strabismus, retinopathy of prematurity and pediatric neuro-ophthalmology. His clinical practice includes an interest in the management of strabismus and amblyopia. In these areas, he has a special interest in using alternatives to patching for the management of amblyopia and using strabis-

SPEAKERS

mus surgery, botulinum toxin and adjustable sutures to treat strabismus. He performs cataract surgery and intraocular lens implantation on children with cataracts. He also has a special interest in pediatric neuro-ophthalmology involving normal and abnormal visual development and the effect of injury and tumor on the visual system of the child.

He is the past-chairman of the Pediatric Eye Disease Investigator Group. He is Medical Director of Governmental Affairs of the American Academy of Ophthalmology and President of the Maryland Society of Eye Physicians and Surgeons.

Connecticut Society of Eye Physicians Financial Interest Disclosure Report 6-10-11

<i>Speaker</i>	<i>Financial Interest Received</i>
Steven Galetta, MD	Biogen, Novartis, Teva
Stephen Lane, MD	Alcon, AMO, Bausch & Lomb, Allergan, Ista, Inspire, WaveTec Vision Care, SMI, LenX, Optimedica, Tear Science
Michael Repka, MD	None

MANAGEMENT PROGRAM

8:00 Registration – Continental Breakfast
in Vendor Expo Hall

8:30 **Coding Part I- Accuracy in Coding: More Important than Ever**

– Paul M. Larson, MBA, MMSe, COMT, COE, CPC,
Corcoran Consulting Group

Objectives: Upon completion of this program, participants should be able to understand that accurate initial coding is key to minimizing exposure to potential recoupment by payers, identify some of the common errors in coding and the risks associated with them, identify some of the elements of the OIC's voluntary Compliance Program, Describe the difference between fraud and innocent mistake, identify a few of the federal statutes related to a compliance program, Understand the governmental oversight process, describe the overpayment refund process.

10:00 Coffee Break

10:30 **Coding Part II- Challenges and Opportunities in Coding for Exams and Diagnostic Testing**

– Paul M. Larson, MBA, MMSe, COMT, COE, CPC,
Corcoran Consulting Group

Objectives: Upon completion of this program, participants should be able to identify the various compo-

MANAGEMENT PROGRAM

nents of the medical history (chief complaint, review of systems, patient history, family and social history), Identify the reason (medical necessity) for the services provided, Provide appropriate and accurate documentation, Identify the pertinent factors to properly code for the more common ophthalmologic diagnostic testing, Identify the pertinent facts related to making a sound choice with CPT modifiers used commonly in the physician-office setting.

- 12:15 Lunch with physicians
Keynote Author – Robert Vare
- 1:15 **AAO Update- PQRI – in Wagon Room**
– Michael Repka, M.D., AAO Medical Director of Governmental Affairs
- 2:00 **Profit Centers/Increasing Your Bottom Line**
– Pamela Fritz
- 3:00 Coffee Break
- 3:30 Risk Management
– Hans Bruhn, MHS, OMIC
Objectives: Identify 3 areas of concern associated with risk. Discuss the importance of documentation and Identify the number one location where indemnity

MANAGEMENT PROGRAM

payments are the highest.

5:00 Certificates and Door Prizes

This program/publication/subscription/etc. has prior approval of the American Academy of Professional Coders for Continuing Education Unites. Granting of this approval in no way constitutes endorsement by the Academy of the program, content or the program sponsor.

TECHNICIANS PROGRAM

8:00 Registration/Continental Breakfast/Vision Expo

**Clinical Challenges in Pediatric Ophthalmology
for the Ophthalmic Technician -
Screenings vs Comprehensive Exams - AAO Positio**

8:30 Introductions & Case Presentations

8:40 Michael Repka, M.D.

9:00 Steve Thornquist, M.D.

9:20 Panel Discussion with Questions and Answers

9:40 **AAO update- Screenings vs. Comprehensive
Exams National update and other Academy
News**

– Michael Repka, M.D.

10:00 Organic Tea, Coffee and Muffin Break

**Clinical Challenges in Neuro-Ophthalmology for the
Ophthalmic Technician**

10:30 Introductions and Case Presentations

11:00 Bob Lesser, M.D.

11:25 Steve Galetta, M.D.

11:50 James Kempton, M.D.

12:00 Panel Discussion with Questions

TECHNICIANS PROGRAM

– Amir Mohsenin, M.D., Joseph Giacometti, M.D.

12:15 **Lunch**

Administrative Challenge for the Ophthalmic Technician Coding and Chart Documentation

1:15 Introductions

1:20 Paul M. Larson, MBA, MMSe, COMT, COE, CPC,
Corcoran Group

2:20 Hans Bruhn, MHS, OMIC

3:10 Panel Discussion with Questions and Answers

3:20 Coffee Break

Clinical Challenges in Cataract for the Ophthalmic Technician

3:45 Introductions and Case Presentations

3:50 Steve Lane, M.D.

4:10 Mitch Gilbert, M.D.

4:30 Panel Discussion with Questions and Answers

5:00 Certificates Door Prizes

*This course has been approved by JCAHPO for
6.0 JCAHPO CE Credits.*

**Save the Date - January 13, 2012
Annual Program at the Aqua Turf
with the following speakers**



Steve Charles, MD is one of the world's leading vitreoretinal surgeons and has developed many of the techniques and devices used by all vitreoretinal surgeons. He has performed over 28,000 vitreoretinal surgeries, lectured in 42 countries and operated in 26, delivered 14 named lectures, over 1000 speaking trips. He authored a leading textbook in the field which is now in the 5th edition and in 5 languages, authored over 140 articles in the medical literature and 44 book chapters. He is on the editorial board of *Retina* and a reviewer for *Ophthalmology*, *Archives of Ophthalmology*, *American Journal of Ophthalmology*, and *British Journal of Ophthalmology*. He is a mechanical and electrical engineer and has 105 issued or pending patents. He is a consultant for Alcon Laboratories and the principal architect of the Alcon Accurus and Alcon Constellation Vision System. He is the Founder of MicroDexterity Systems, developing robots for dexterity enhancement for minimally invasive knee and hip replacement, spine surgery, and skull base neurosurgery. He is the President of Infinity Research, Inc. He has received the Wacker Medal from the Club Jules Gonin, the first Founders Medal from the Vitreous Society, was inducted into the University of Miami School of Medicine Medical Alumni Association Hall of Fame, and

was named by *Ocular Surgery News* as one of the top ten innovators in the past 25 years. He is a Clinical Professor at the University of Tennessee and an Adjunct Professor at Columbia College of Physicians and Surgeons and Chinese University of Hong Kong. He is a member of the Retina Society, Macula Society, Club Jules Gonin, American Society of Retinal Specialists, and the American Academy of Ophthalmology.

After four years in engineering school, he completed medical school at the University of Miami School of Medicine. He did research all four medical school years at the Bascom Palmer Eye Institute. After a medical internship at Jackson Memorial Hospital in Miami he completed a residency the Bascom Palmer Eye Institute followed by a two year Clinical Associate appointment at the National Eye Institute (NIH); focused on vitreoretinal surgery, angiogenesis research and medical device engineering.

Commercial, multi-engine, instrument rated pilot with type ratings in Citation 500 and 560 jets, currently flies a Citation Encore.



Thomas Harbin, MD entered private practice with Eye Consultants of Atlanta after a residency at the Wilmer Institute from 1971 - 1974 and a fellowship in glaucoma at the Glaucoma Center at Washington University from 1974-1975. He resides in Atlanta with his wife Ellen. He served on the clinical faculty at Emory and his current title is Clinical Professor Emeritus.

He continues to practice at Eye Consultants. His first book, *Waking Up Blind*, was published in December, 2009 and his second book, *What Every Doctor Should Know... But was Never Taught in Medical School*, was published in July 2010.



L. Jay Katz, MD is a Professor of Ophthalmology at Jefferson Medical College, Thomas Jefferson University, in Philadelphia, Pennsylvania and Director of the Glaucoma Service at Wills Eye Institute. Dr. Katz received his MD degree from Yale University Medical School, New Haven, and completed an internship in Internal Medicine at the University of Virginia, Charlottesville, Virginia, a residency in Ophthalmology at Yale, and a Fellowship in Glaucoma at Wills Eye Hospital.

Dr. Katz has been the recipient of various awards, including the American Academy of Ophthalmology (AAO) Senior Achievement Award in 2002 and the Joint Commission on Allied Health Personnel in Ophthalmology's Faculty Award in 2003. He was named Distinguished Alumnus of the Yale University Eye Center in 2003 and became a Honored Life Member of the Philadelphia Ophthalmic Club in 2007.

Dr. Katz has published more than 120 articles in such journals as *Archives of Ophthalmology*, *the American Journal of Ophthalmology*, *Ophthalmology*, and *the Journal of Glaucoma*. He is an Editorial Board member for *Journal of Glaucoma*, *Survey of Ophthalmology*, *Clinical*

Therapeutics and Graefe's Archives of Clinical and Experimental Ophthalmology. He has authored, coauthored, or edited more than 30 books and book chapters.



Richard Mackool, MD is Director of The Mackool Eye Institute, the first ambulatory surgery center in New York. He has authored hundreds of articles, two textbooks and several textbook chapters on the subject of cataract extraction and intraocular lens implantation. His monthly column Phaco/Tipssm has appeared in *Ocular Surgery News* since 1990. Dr. Mackool has been granted approximately 125 U.S. and international patents for inventions in the areas of cataract extraction, phacoemulsification and intraocular lens implant designs.



Ruth D. Williams, MD is the President-Elect of the American Academy of Ophthalmology. She previously served on the AAO Board of Trustees and then as AAO Secretary for Member Services. She represented ophthalmology at the American Medical Association for nearly a decade, serving as chair of the Specialty Section and the Ophthalmology Section.

Dr. Williams is the CEO of the Wheaton Eye Clinic, one of the largest ophthalmology clinics in the Midwest. Located in the Chicago suburbs, the 65-year-old Wheaton Eye

Clinic provides subspecialty eye care to over 130,000 patients each year. She is a glaucoma consultant.

A popular speaker, Dr. Williams has given invited lectures at national and international medical conferences, including Kuwait, Brazil, China, Canada, and India. She has appeared on a dozen major television networks and talk shows. She has been interviewed by numerous magazines including *Health*, *Women's Health*, *Shape*, and *Good Housekeeping*. Recent print interviews include *The New York Times* and the *Chicago Tribune*. Dr. Williams is a clinical spokesperson for the American Academy of Ophthalmology

Dr. Williams attended medical school at Rush Presbyterian St. Luke's Medical Center in Chicago. She interned at West Suburban Hospital Medical Center, and then completed a residency in ophthalmology at the California Pacific Medical Center in San Francisco and a fellowship in glaucoma at the University of California, San Francisco

The mother of three teenagers, Dr. Williams is married to ophthalmologist Stephen C. Gieser, MD, MPH.

**Don't miss this incredible program!
Register early and take advantage of the
Management & Technician Programs
for your staff.**

Alcon

www.alconlabs.com

World Class
Pharmaceuticals For
Excellent Patient Care



TRAVATAN
Travoprost ophthalmic solution 0.01%

www.travatan.com



Patanol
Olopatadine hydrochloride
ophthalmic solution 0.1%

www.patanol.com



Vigamox
Moxifloxacin hydrochloride ophthalmic solution 0.1%

Learn more from us at www.vigamox.com

www.vigamox.com



Optical Company Inc.
Committed to Independent Eyecare

Ask us about our full-service, in-house Crizal® processing lab!

Dan Mattaboni, Branch Manager
Rod MacLeod, Sales Rep

451 Meriden Road
Waterbury, CT 06705
800.873.5367



Crizal and Varilux are registered trademarks and TD2 is a trademark of Essilor International, S.A.

Crizal

TD2

VARILUX



P.O. Box 280023

East Hartford, CT 06128-0023

Phone (860) 289-6023

National WATS: (800) 842-8622

Fax: (860) 289-0164 ~ Fax

WATS (800) 441-8866

www.precision-optical-co.com

e-mail precision.optical@snet.net

PRECISION OPTICAL CO.

is proud to support the CSEP.

Precision is also proud of its independence—over sixty years!

We have supported Connecticut doctors for many years and will continue to service the association and its members for many years to come.

Please call us for all you optical needs.

We specialize in servicing almost all products.

For Moderate and Severe Dry Eye Due to Decreased Tear Production

DROP DROP DROP DROP
DROP DROP DROP DROP
DROP DROP DROP DROP
DROP DROP DROP DROP
DROP DROP DROP DROP
DROP DROP DROP DROP
DROP DROP DROP DROP
DROP DROP DROP DR

She's
SATISFEYED™

What can be more satisfying to
Dry Eye patients than producing
more of their own tears?

RESTASIS® Ophthalmic Emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

Important Safety Information

RESTASIS® is contraindicated in patients with active ocular infections and has not been studied in patients with a history of

herpes keratitis. The most common adverse event was ocular burning (upon instillation)—17%.

Other events reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).

Please see Brief Summary of the Prescribing Information on the adjacent page.

Over 2,000,000
Rx's Written

**Enough With
The Tears.**

**With
RESTASIS®
She's Making
More Of
Her Own.**



Restasis® B.I.D.
(Cyclosporine Ophthalmic Emulsion) 0.05%

The Best Tears Are Their Own Tears

ALLERGAN **INSPIRE**

©2005 Allergan, Inc., Irvine, CA 92612
* and™ Marks owned by Allergan, Inc. SIMC05850

PRESCRIBE RESTASIS[®] OPHTHALMIC EMULSION—

THE ONLY THERAPY PROVEN TO INCREASE TEAR PRODUCTION^{1,2}



RESTASIS[®] (cyclosporine ophthalmic emulsion) 0.05% Sterile, Preservative-Free

INDICATIONS AND USAGE

RESTASIS[®] ophthalmic emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

CONTRAINDICATIONS

RESTASIS[®] is contraindicated in patients with active ocular infections and in patients with known or suspected hypersensitivity to any of the ingredients in the formulation.

WARNING

RESTASIS[®] ophthalmic emulsion has not been studied in patients with a history of herpes keratitis.

PRECAUTIONS

General: For ophthalmic use only.

Information for Patients:

The emulsion from one individual single-use vial is to be used immediately after opening for administration to one or both eyes, and the remaining contents should be discarded immediately after administration.

Do not allow the tip of the vial to touch the eye or any surface, as this may contaminate the emulsion.

RESTASIS[®] should not be administered while wearing contact lenses. Patients with decreased tear production typically should not wear contact lenses. If contact lenses are worn, they should be removed prior to the administration of the emulsion. Lenses may be reinserted 15 minutes following administration of RESTASIS[®] ophthalmic emulsion.

Carcinogenesis, Mutagenesis, and Impairment of Fertility:

Systemic carcinogenicity studies were carried out in male and female mice and rats. In the 78-week oral (diet) mouse study, at doses of 1, 4, and 16 mg/kg/day, evidence of a statistically significant trend was found for lymphocytic lymphomas in females, and the incidence of hepatocellular carcinomas in mid-dose males significantly exceeded the control value.

In the 24-month oral (diet) rat study, conducted at 0.5, 2, and 8 mg/kg/day, pancreatic islet cell adenomas significantly exceeded the control rate in the low dose level. The hepatocellular carcinomas and pancreatic islet cell adenomas were not dose related. The low doses in mice and rats are approximately 1000 and 500 times greater, respectively, than the daily human dose of one drop (28 µL) of 0.05% RESTASIS[®] BID into each eye of a 60 kg person (0.001 mg/kg/day), assuming that the entire dose is absorbed.

Cyclosporine has not been found mutagenic/genotoxic in the Ames Test, the V79-HGPRT Test, the micronucleus test in mice and Chinese hamsters, the chromosome-aberration tests in Chinese hamster bone-marrow, the mouse dominant lethal assay, and the DNA-repair test in sperm from treated mice. A study analyzing sister chromatid exchange (SCE) induction by cyclosporine using human lymphocytes *in vitro* gave indication of a positive effect (i.e., induction of SCE).

No impairment in fertility was demonstrated in studies in male and female rats receiving oral doses of cyclosporine up to 15 mg/kg/day (approximately 15,000 times the human daily dose of 0.001 mg/kg/day) for 9 weeks (male) and 2 weeks (female) prior to mating.

Pregnancy-Teratogenic effects:

Pregnancy category C.

Teratogenic effects: No evidence of teratogenicity was observed in rats or rabbits receiving oral doses of cyclosporine up to 300 mg/kg/day during organogenesis. These doses in rats and rabbits are approximately 300,000 times greater than the daily human dose of one drop (28 µL) 0.05% RESTASIS[®] BID into each eye of a 60 kg person (0.001 mg/kg/day), assuming that the entire dose is absorbed.

Non-Teratogenic effects: Adverse effects were seen in reproduction studies in rats and rabbits only at dose levels toxic to dams. At toxic doses (rats at 30 mg/kg/day and rabbits at 100 mg/kg/day), cyclosporine oral solution, USP, was embryo- and fetotoxic as indicated by increased pre- and postnatal mortality and reduced fetal weight together with related skeletal retardations. These doses are 30,000 and 100,000 times greater, respectively than the daily human dose of one-drop (28 µL) of 0.05% RESTASIS[®] BID into each eye of a 60 kg person (0.001 mg/kg/day), assuming that the entire dose is absorbed. No evidence of embryofetal toxicity was observed in rats or rabbits receiving cyclosporine at oral doses up to 17 mg/kg/day or 30 mg/kg/day, respectively, during organogenesis. These doses in rats and rabbits are approximately 17,000 and 30,000 times greater, respectively, than the daily human dose.

Offspring of rats receiving a 45 mg/kg/day oral dose of cyclosporine from Day 15 of pregnancy until Day 21 post partum, a maternally toxic level, exhibited an increase in postnatal mortality; this dose is 45,000 times greater than the daily human topical dose, 0.001 mg/kg/day, assuming that the entire dose is absorbed. No adverse events were observed at oral doses up to 15 mg/kg/day (15,000 times greater than the daily human dose).

There are no adequate and well-controlled studies of RESTASIS[®] in pregnant women. RESTASIS[®] should be administered to a pregnant woman only if clearly needed.

Nursing Mothers:

Cyclosporine is known to be excreted in human milk following systemic administration but excretion in human milk after topical treatment has not been investigated. Although blood concentrations are undetectable after topical administration of RESTASIS[®] ophthalmic emulsion, caution should be exercised when RESTASIS[®] is administered to a nursing woman.

Pediatric Use:

The safety and efficacy of RESTASIS[®] ophthalmic emulsion has not been established in pediatric patients below the age of 16.

Geriatric Use:

No overall difference in safety or effectiveness has been observed between elderly and younger patients.

ADVERSE REACTIONS

The most common adverse event following the use of RESTASIS[®] was ocular burning (17%).

Other events reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).

Rx Only



©2004 Allergan, Inc.
Irvine, CA 92612, U.S.A.
* Marks owned by Allergan, Inc.
US PAT 4,649,047; 4,839,342; 5,474,979.

References: 1. Data on file, Allergan, Inc. 2. Sall K, Stevenson GD, Mundorf TK, Reis BL, and the CAa Phase 3 Study Group. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. *Ophthalmology*. 2000; 107(4):631-639.

The CSEP Annual Scientific Education Programs are an opportunity for ophthalmologists to identify and discuss critical issues facing their profession. These programs are designed to present recent advances in the diagnosis and treatment of eye disease, offering symposia, scientific papers and videos. The CSEP programs are designed to meet the clinical and educational needs of its members and the objectives set forth by the CSEP education committee.

*Vincent deLuise, M.D.
CSEP Education Chair*